Ralpancizumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized (from mouse) |
| Target | neural apoptosis-regulated proteinase 1 |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number | 1407495-04-8 |
| ChemSpider | none |
| Chemical and physical data | |
| Formula | C6422H9922N1730O2012S54 |
| Molar mass | 145.3 kg/mol |
Ralpancizumab[1] is a monoclonal antibody designed for the treatment of dyslipidemia.[2]
This drug was developed by Pfizer.
References
- ↑ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4).
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Ralpancizumab, American Medical Association.
This article is issued from Wikipedia - version of the 2/28/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.